GeneDx Holdings Corp. (WGS) Stock
5 of the hedge funds AlphaScala tracks reported WGS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $110.54M. Company insiders reported 0 open-market buys and 13 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which hedge funds own WGS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 1.61M | $110.54M | +22% |
| Citadel Ken Griffin | 865K | $59.41M | +34% |
| Millennium Management Israel Englander | 156K | $10.68M | +4% |
| Point72 Steve Cohen | 97K | $6.68M | +28% |
| D.E. Shaw David Shaw | 39K | $2.67M | +106% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are GeneDx Holdings Corp. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 16, 26 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 1.6K | $155K |
| Sep 16, 26 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 148 | $14K |
| Sep 16, 26 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 1.5K | $148K |
| Sep 16, 26 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 4.1K | $407K |
| Sep 16, 26 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 3.0K | $301K |
| Sep 16, 26 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 586 | $55K |
| Sep 16, 26 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 52 | $5K |
| Sep 16, 26 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 541 | $52K |
| Sep 16, 26 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 1.5K | $144K |
| Sep 16, 26 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 1.1K | $107K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →WGS price chart
Powered by TradingViewWhat does GeneDx Holdings Corp. do?
GeneDx Holdings Corp. is a leading genomics company specializing in genetic testing services for the diagnosis of rare and complex genetic disorders. It provides advanced whole exome and genome sequencing, along with targeted gene panels and microarray testing, to deliver rapid, precise, and actionable clinical insights that inform personalized treatment plans and improve patient outcomes. The company leverages one of the largest rare disease datasets, powered by millions of tests, exomes, genomes, and phenotypic data points, enhanced by AI tools and expert interpretation to achieve higher diagnostic yields than traditional methods. GeneDx supports healthcare providers in addressing conditions such as autism spectrum disorders, developmental delays, epilepsy, cardiomyopathy, and various inherited diseases across pediatric and adult populations. Its offerings facilitate precision medicine by accelerating diagnoses, reducing diagnostic odysseys, and aiding drug discovery through comprehensive genomic analysis. Headquartered in Stamford, Connecticut, GeneDx Holdings Corp. serves clinicians, patients, and health systems seeking to integrate cutting-edge genomics into routine care.